Changes in plasma membrane fluidity of immortal rodent cells induced by anticancer drugs doxorubicin, aclarubicin and mitoxantrone

Cell Biology International

Volumn 23, Issue 7, 1999, Pages 497-506

  Jedrzejczak, Malgorzata ^a   Koceva Chyla, Aneta ^a   Gwozdzinski, Krzysztof ^a   Józwiak, Zofia ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Aclarubicin; B14 fibroblasts; Doxorubicin; ESR; Fluorescence anisotropy; Membrane fluidity; Mitoxantrone; NIH 3T3 fibroblasts

Indexed keywords

ACLARUBICIN; DOXORUBICIN; FLUORESCENT DYE; MITOXANTRONE; STEARIC ACID DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE FLUIDITY; CELL STRAIN 3T3; CHINESE HAMSTER; CONTROLLED STUDY; DRUG EFFECT; ELECTRON SPIN RESONANCE; FIBROBLAST; FLUORESCENCE SPECTROSCOPY; LIPID BILAYER; MOUSE; NONHUMAN;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS; RODENTIA;

EID: 0033500105     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1006/cbir.1999.0399     Document Type: Article

References (43)

1. Arancia G, Donelli G. Cell membranes as target for anticancer agents. Pharmacol Res. 24:1991;205-217.
2. Burns CP. Membranes and cancer chemotherapy. Cancer Invest. 6:1988;439-451.
3. Burns CP, Haugstad BN, Mossman CJ, North JA, Ingraham LM. Membrane lipid alteration: effect on cellular uptake of mitoxantrone. Lipids. 23:1988;393-397.
4. Cassaza AM. Anthracyclines as inducers of tumor cell differentation. Lown JW. Bioactive Molecules. Vol. 6. 1988;715-734 Elsevier Science, Amsterdam.
5. Constantinides PP, Wang YY, Burke TG, Tritton TR. Transverse location of anthracyclines in lipid bilayers. Paramagnetic quenching studies. Biophys Chem. 35:1990;259-264.
6. Crane FL, MacKellar WC, Morre DJ, Ramasarma T, Goldenberg H, Grebing C, Low H. Adriamycin affects plasma membrane redox function. Biochem Biophys Res Commun. 93:1980;746-754.
7. Crane FL, Sun IL, Clark MG, Grebing C, Low H. Transplasma-membrane redox systems in growth and development. Biochim Biophys Acta. 811:1985;233-264.
8. Dasdia T, Di Marco A, Goffredi M, Minghetti A, Necco A. Ion level and calcium fluxes in HeLa cells after adriamycin treatment. Pharmacol Res Commun. 11:1979;19-29.
9. Donner M, Muller S, Stoltz JF. Importance of membrane fluidity determinations. J Mal Vasc. 15:1990;353-358.
10. Gallois L, Fiallo M, Garnier-Suillerot A. Comparison of the interaction of doxorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study. Biochim Biophys Acta. 1370:1998;31-40.
11. Garnier-Suillerot A, Gattegno L. Interactions of adriamycin with human erythrocyte membranes. Role of the negatively charged phospholipids. Biochim Biophys Acta. 936:1988;50-60.
12. Goldstein DB. The effect of drugs on membrane fluidity. Ann Rev Pharmacol Toxicol. 24:1984;43-64.
13. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM. Adriamycin inhibits the formation of non-bilayer lipid structures in cardiolipin-containing model membranes. Biochim Biophys Acta. 685:1982;137-143.
14. Goormaghtigh E, Ruysschaert JM. Anthracycline glycoside-membrane interactions. Biochim Biophys Acta. 779:1984;271-288.
15. Grace T, Ehrlich YH, Tritton TR. Mechanism of membrane-mediated cytotoxicity by adriamycin. Chandra P. New Experimental Modalities in the Treatment of Neoplasia. 1986;195-202 Plenum Press, New York.
16. Guffy MM, North JA, Burns CP. Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res. 44:1984;1863-1866.
17. Herman E, Zhang J, Hasinhoff BB, Clark JR Jr, Ferran VG. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol. 29:1997;2415-2430.
18. Holm B, Jensen PB, Sehested M, Hansen HH. In vivo inhibition of etoposide-mediated apoptosis, toxicity and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin. Cancer Chemother Pharmacol. 34:1994;503-508.
19. Kessel D. Enhanced glycosylation induced by adriamycin. Mol Pharmacol. 16:1979;306-312.
20. Kohlschutter A, Hubner C, Gartner J. Decreased membrane fluidity of lymphocytes from patients with juvenile neuronal ceroid-lipofuscinosis. Am J Med Genet Suppl. 5:1988;203-207.
21. Lameh J, Chuang RY, Israel M, Chuang LF. Nucleoside uptake and membrane fluidity studies on Ntrifluoroacetyladriamycin-14-O-hemiadipate-treated human leukemia and lymphoma cells. Cancer Res. 49:1989;2905-2908.
22. Marutaka M, Iwagaki H, Suguri T, Tanaka N, Orita K. Alterations of membrane fluidity in K562 cells exposed to the anticancer drug adriamycin. Res Commun Mol Pathol Pharmacol. 85:1994;163-170.
23. Morceau F, Aries A, Lahlil R, Devy L, Jardillier JC, Jeannesson P, Trentesaux C. Evidence for distinct regulation processes in the aclacinomycin- and doxorubicin-mediated differentiation of human erythroleukemic cells. Biochem Pharmacol. 51:1996;839-845.
24. Morrisett JD, Pownall HJ, Plumlee RT, Smith LC, Zehner ZE. Multiple thermotropic phase transition in Escherichia coli membranes and membrane lipids. A comparison of results obtained by nitroxyl stearate paramagnetic resonance, pyrene excimer fluorescence, and enzyme activity measurements. J Biol Chem. 250:1975;6969-6976.
25. Murphree SA, Cummingham KM, Hwang AC, Sartorelli AC. Effect of adriamycin on surface properties of sarcoma 180 ascites cells. Biochem Pharmacol. 25:1976;1227-1231.
26. Murphree SA, Murphy D, Sartorelli AC, Tritton TR. Adriamycin-liposome interactions. A magnetic resonance study of the differential effects of cardiolipin on drug induced fusion and permeability. Biochim Biophys Acta. 691:1982;97-105.
27. Murphree SA, Tritton TR. Effect of DOX on liposomal and cellular membranes studied by magnetic resonance. Fed Proc. 38:1979;258-263.
28. Murphree SA, Tritton TR, Smith PL, Sartorelli AC. Adriamycin induced changes in the surface membrane sarcoma 180 ascites cells. Biochim Biophys Acta. 649:1981;317-324.
29. Muzulu SI, Bing RF, Norman RI, Burden AC. Human red cell membrane fluidity and calcium pump activity in normolipidaemic type II diabetic subjects. Diabet Med. 11:1994;763-767.
30. Oth D, Begin M, Bischoff P, Leroux JY, Mercier G, Bruneau C. Induction, by adriamycin and mitomycin C, of modification in lipid composition, size distribution, membrane fluidity and permeability of cultured RDM4 lymphoma cells. Biochim Biophys Acta. 900:1987;198-208.
31. Rogers KE, Carr BI, Tokes ZA. Cell surface-mediated cytotoxicity of polymer-bound Adriamycin against drug resistant hepatocytes. Cancer Res. 43:1983;2741-2748.
32. Siegfried JA, Tritton TR. Adriamycin enhances the agglutination rate of sensitive, but not resistant S180 cells. A New England Pharmac. 8:1979;18-24.
33. Smith PJ, Morgan SA, Fox ME, Watson JV. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol. 40:1990;2069-2078.
34. Stuhne-Sekalec L, Stanacev NZ. Temperature-induced changed spin-labelled radioactive lipids in isolated guinea pig liver microsomal membranes before and in mitochondrial membranes after translocation. Can J Biochem. 56:1978;722-728.
35. Szwarocka A, Fiet I, Józwiak Z, Krykowski E, Robak T. Plasma membrane as a site of interaction of mitoxantrone in human erythrocytes. Franconi C, Arcangeli G, Cavaliere R. Hyperthermic Oncology. 1996;670-672 Publisher, Roma.
36. Szwarocka A, Robak T, Krykowski E, Józwiak Z. Interaction of anthracyclines with human erythrocytes at hyperthermic temperature. Int J Pharmacol. 135:1996;167-176.
37. Tokes ZA, Rogers KE, Rembaum A. Synthesis of adriamycin - coupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity. Proc Natl Acad Sci U S A. 79:1982;2026-2030.
38. Tritton, TR, Hickman, JA, 1985, Cells surface membranes as chemotherapeutic target, Muggia, FM, Experimental and clinical progress in cancer chemotherapy, Boston, Martinus Nijhoff Publishers, 81, 131.
39. Tritton TR, Murphree SA, Sartorelli AC. Adriamycin: a proposal on the specificity of drug action. Biochem Biophys Res Commun. 84:1978;802-808.
40. Tritton TR, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering the cells. Science. 217:1982;248-250.
41. Van der Meer BW. Fluorescence studies on biological membranes. Hilderson HJ, Harris JR. Subcellular Biochemistry. 1988;1-53 Plenum Press, New York.
42. Zubenko GS, Cohen BM, Boller F, Malinakova I, Keefe N, Chojnacki B. Platelet membrane abnormality in Alzheimer's disease. Ann Neurol. 22:1987;237-244.
43. Zuckier G, Tritton TR. Adriamycin causes up regulation of epidermal growth factor receptors in actively growing cells. Exp Cell Res. 148:1983;155-161.